Generics: Volume vs Spend
Generics fill 90% of US prescriptions yet capture only ~17% of spending (FDA; AAM 2024).
Specialty: Spend vs Volume
The mirror image: specialty drugs are ~2% of prescriptions but ~55% of spending (IQVIA 2024).
Cash-Price Floors
$2.00 metformin (Cost Plus)$4 Walmart generics~$10 Costco top-200Cost Plus: cost + 15% + $5$2.9 trillion generic savings 2014-2023
What competitive generics do to cash prices once the patent cliff clears.
Roughly 30% of US adults report not filling a prescription, skipping doses, or cutting pills in half because of cost.Source: KFF Health Tracking Poll on Drug Costs 2023
US Drug Spending
$487 billion#1 US net prescription drug spending in 2024 (after rebates), per IQVIA.
$722 billion#2 US gross prescription drug spending at invoice prices in 2024 before rebates and discounts.
Source: IQVIA Use of Medicines
~9.1%#3 share of total US national health expenditure (NHE) attributable to retail prescription drugs in 2023.
6.5 billion#4 US prescriptions dispensed in 2024 (retail and mail order combined).
Source: IQVIA 2024
66%#6 of US adults take at least one prescription drug.
~24%#7 of US adults aged 18+ take 5 or more prescription medications regularly.
$1,432#8 mean annual out-of-pocket spending on prescription drugs among Medicare beneficiaries in 2022.
Source: KFF Medicare Part D Key Facts
~30%#9 of US adults report not filling a prescription, skipping doses, or cutting pills due to cost.
$56,000#10 median annual list price of a newly launched US drug in 2023, more than 5x the 2008 median.
Brand vs Generic Pricing
~17%#12 share of total US prescription drug spending captured by generics, despite filling 90% of prescriptions.
85%#13 typical cash-price drop from brand to generic within 24 months of first generic competition.
3.4x#14 price premium of single-source generics versus generics with 4 or more ANDA holders.
$2.9 trillion#15 cumulative US savings from generic and biosimilar drug use over the last decade (2014-2023).
39%#16 additional price reduction delivered by the second ANDA holder versus the first.
85%+#17 share of brand-to-generic transitions in the RxGrab 2026 audit that achieved a price drop of 70% or more.
Source: RxGrab 2026 Patent Cliff Audit
$2.00#18 minimum cash price for a 30-day supply of metformin 500mg at Mark Cuban Cost Plus Drugs in 2026.
Source: costplusdrugs.com public catalog
$4#19 Walmart cash price for many generics on the Walmart $4 prescription list (30-day supply).
Source: Walmart $4 Prescription Program
7#20 stalled-generic cases identified in the RxGrab 2026 audit (post-launch price retained 50%+ of brand for 12+ months).
Source: RxGrab 2026 Patent Cliff Audit
Patent Expiry Trends
$300 billion+#21 estimated global brand drug revenue exposed to patent expiry between 2025 and 2030.
11 months#22 median time from FDA Orange Book composition-of-matter patent expiry to first generic ANDA approval.
Source: RxGrab 2026 Patent Cliff Audit
5 of 50#23 brand drugs in the RxGrab 2026 audit remain brand-only with no approved generic: Ozempic, Wegovy, Jardiance, Eliquis, Xarelto.
Source: RxGrab 2026 Patent Cliff Audit
$55 billion+#24 combined 2024 US sales of the five brand-only blockbusters in the RxGrab cohort.
Source: company 10-K disclosures (Novo Nordisk, BMS, Pfizer, Boehringer Ingelheim, Janssen) compiled in RxGrab 2026 audit
2031-2033#25 estimated first generic launch window for semaglutide (Ozempic and Wegovy active ingredient).
Source: ASPE drug pricing analyses and Novo Nordisk patent disclosures
2026#26 Inflation Reduction Act maximum-fair-price effective date for the first 10 negotiated drugs (Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, NovoLog).
132#27 patents AbbVie filed around adalimumab (Humira), the canonical patent thicket case.
~7 years#28 US biosimilar competition delay for Humira after the original composition-of-matter patent expired in 2016.
Source: FTC pay-for-delay analyses and FDA biosimilar approval records
$3 billion+#29 annual revenue settlement-permitted entry deals can preserve for a brand sponsor on a $5B+ blockbuster per year of delay.
Source: FTC Pay-for-Delay Reports
15#30 drugs CMS will negotiate for Medicare Part D in the second IRA cycle (effective January 2027).
Source: CMS IRA Negotiation Cycle 2
Generic Approval Rates
~860#31 Abbreviated New Drug Applications (ANDAs) approved by FDA in fiscal year 2023.
Source: FDA CDER Data Dashboard
~30 months#32 median FDA approval time for an Abbreviated New Drug Application (ANDA) in 2023, including review cycles.
Source: FDA ANDA Approvals Tracker
180 days#33 exclusivity granted to the first ANDA filer who challenges a brand's patent and is approved (Hatch-Waxman 180-day exclusivity).
Source: FDA 180-Day Exclusivity Statute
~50#34 First Generics approved by FDA in 2023 (drugs receiving their first ANDA approval).
Source: FDA First Generic Drug Approvals
9#36 drugs in the RxGrab 2026 audit where the brand sponsor launched a 505(b)(2) line-extension within 36 months of original molecule patent expiry.
Source: RxGrab 2026 Patent Cliff Audit
~30%#37 share of post-launch generic unit volume captured by authorized generics in their first 12 months.
Source: FDA Authorized Generic Drugs List and GAO 2019
~20%#38 of FDA-approved brand drugs have an authorized generic listed by the brand sponsor at some point post-launch.
$15 million+#39 typical cost to develop and gain ANDA approval for a single complex generic in 2024.
Source: AAM 2024 industry report
~62%#40 first-cycle ANDA approval rate after FDA's Drug Competition Action Plan reforms (up from ~9% in 2015).
Source: FDA Drug Competition Action Plan
FDA Orange Book Statistics
1980#41 the year the FDA Orange Book began publication, formalizing therapeutic equivalence ratings (AB, BX, etc.).
AB#42 rating denotes therapeutic equivalence and pharmacy-level substitutability without prescriber authorization (in most states).
~85%#43 of multi-source drug products in the Orange Book are AB-rated, signaling broad substitutability.
Source: FDA Orange Book aggregates
BX#44 rating denotes "data are insufficient to determine therapeutic equivalence" and is the most common reason a state pharmacy board blocks substitution.
Source: FDA Orange Book TE codes
~50#45 drug products listed in the FDA Narrow Therapeutic Index list, where dose precision matters more for substitution decisions.
3 years#46 of marketing exclusivity granted by FDA for a new indication of an approved drug (data exclusivity).
Source: FDA Patents and Exclusivity FAQ
5 years#47 of new chemical entity exclusivity granted by FDA at first approval, blocking ANDA filings during that window.
Source: FDA Patents and Exclusivity FAQ
7 years#48 of orphan drug exclusivity granted under the Orphan Drug Act for designated rare-disease indications.
Source: FDA Orphan Drug Designation
6 months#49 of pediatric exclusivity granted by FDA for completing requested pediatric studies, added to existing exclusivity.
Source: FDA Pediatric Exclusivity
~2,000#50 drug products on the FDA Discontinued Drug Products List (Orange Book Discontinued Section) as of 2024.
Drug Shortages
309#51 active US drug shortages tracked by ASHP at end of 2023, the highest in a decade.
Source: ASHP Drug Shortages
~70%#52 of US drug shortages reported by ASHP affect generic injectables.
Source: ASHP shortage analyses
~50%#53 of US active pharmaceutical ingredient (API) facilities are located outside the United States, primarily in India and China.
2023#54 the year US oncology drug shortages drew national press coverage following carboplatin and cisplatin supply failures.
Source: FDA Drug Shortages and ASHP shortage records
15.4 months#55 average duration of an active US drug shortage in 2023 per ASHP tracking.
5#56 primary root causes of drug shortages identified by FDA: manufacturing quality issues, supply of raw materials, capacity constraints, business decisions, and natural disasters.
Specialty Drugs
~55%#57 share of US prescription drug spending captured by specialty drugs, despite only ~2% of prescriptions.
Source: IQVIA Use of Medicines 2024
$84,000#58 average annual list price of a specialty drug in the US in 2023.
~50#59 approved biosimilars in the US as of 2024 across roughly 12 reference biologics.
$23.6 billion#60 cumulative US savings from biosimilars 2015-2023 per IQVIA Institute estimates.
2023#61 the year Humira biosimilars launched at scale in the US, ending Humira's 20-year market exclusivity.
Source: FDA biosimilar approval timeline
~18%#62 typical first-year US list-price discount of a biosimilar versus the originator biologic, well below the 50%+ Europe achieves.
Source: IQVIA Biosimilars Outlook
$3.5 million#63 US list price of one-time gene therapy Hemgenix at launch in 2022, the highest-priced drug in the world at the time.
$26,000-$48,000#64 per-month list price range for new oncology drug launches in 2022-2023.
Prior Authorization
~94%#65 of physicians report that prior authorization delays patient access to necessary care.
39#66 prior authorization requests handled per physician per week on average.
~30%#67 of prior authorization requests for prescriptions are initially denied, of which the majority are eventually approved on appeal.
~$93 billion#68 estimated annual US administrative burden of prior authorization across the healthcare system.
2026#69 the year CMS final rule (CMS-0057-F) requires Medicare Advantage and other payers to implement electronic prior authorization APIs.
~80%#70 of US specialty drug prescriptions require prior authorization.
Source: IQVIA Specialty Drug Access
Pharmacy Discounts
$5#71 Mark Cuban Cost Plus Drugs flat dispensing fee added to the cost-plus-15% markup model for each prescription.
Source: Cost Plus Drugs pricing model
67%#72 average price gap between Mark Cuban Cost Plus Drugs and GoodRx coupon-low across 32 audited generics in the RxGrab 2026 study.
Source: RxGrab 2026 Patent Cliff Audit
~80%#73 typical maximum savings GoodRx markets versus the unsubsidized retail cash price, varying widely by drug.
~32%#74 share of US adults who report using a prescription drug discount card at least once.
Source: KFF Health Tracking Poll
~$10#75 Costco Pharmacy generic cash price for many top-200 oral solids without a Costco membership requirement (state-dependent).
Source: Costco Pharmacy public price lists
$1.99-$5#76 Amazon Pharmacy RxPass flat-fee tier for unlimited eligible generics for Prime members on select medications.
Source: Amazon Pharmacy RxPass
~50#77 generics on the Walmart $4 Prescription Program at the standard 30-day fill, with $10 for 90-day.
Source: Walmart $4 Prescription List
2024#78 the year GoodRx reported $760M+ annual revenue, illustrating the scale of US discount-card economics.
International Comparison
2.78x#79 US drug prices on average versus a basket of 33 OECD comparator countries (gross prices, 2022 RAND study).
3.44x#80 US prices versus OECD comparators for brand-name (originator) drugs specifically per RAND 2022.
Source: RAND Corporation 2022 RR-A788-1
~84%#81 US generic drug prices versus OECD comparators (US generics are notably cheaper than OECD generics in some cases).
Source: RAND Corporation 2022 RR-A788-1
~50%#82 typical first-year European biosimilar discount versus originator biologic, more than double the US first-year discount.
Source: IQVIA Biosimilars 2023-2027
2003#83 the year the Medicare Modernization Act prohibited Medicare from directly negotiating drug prices, a constraint partially reversed by the 2022 Inflation Reduction Act for selected drugs.
Source: CMS IRA history
~$237 billion#84 estimated 10-year US federal savings (2022-2031) from the Inflation Reduction Act drug pricing provisions per CBO.
2026#85 the year RxGrab will refresh this dataset; the brand-to-generic pricing landscape changes meaningfully in 12-month windows around major patent cliffs.
Source: RxGrab 2026 Patent Cliff Audit annual refresh policy